Shire Plc ADS, Each Representing Three Ordinary Shares (SHPG) Quote

http://finance.yahoo.com/news/announcement-notice-shire-abbvie-board-234400720.html

Gawd I love this stock!!!!! Thank you SHPG

Ok figured out - ADR on SHIRE is 3:1 so math on this one

So Shire has a 3:1 3 for 1 ADR and the math would be . . . ($68.55 offer from Takeda to shire *3 ADR/Stk) / 128.77 Shire close on March 27, 2019 = 1.5970 multiple or 60% premium that they are givinng shareholders.

Plus the 36.83 in stock

Plus the cash component $29.38 cash / SHPG share

So how does the Shire shareholder make out on this deal?

Takeda shares tumbled as much as 9.3 percent in early trading in Tokyo on Wednesday. The Japanese company is offering the equivalent of 49 pounds ($68.55) per share, including 27.26 pounds in stock and 21.75 pounds in cash, Shire said in a statement. That’s a 60 percent premium to Shire’s closing share price on March 27, before Takeda disclosed it was interested in the US drug maker.

Where is the 60percent premium to Close of March 27 2018 at shire 128.87


I see a 4 percent premium if you work the pounds of stock and pounds of cash into dollars and get 134.76 over March 27 2018 close.

Ok so takeda is buying shire. So how much will each shareholders stock be worth ? With this deal

Riding and Raising that BULL flag since End of March- New Drug, Strong like Bull we dont want your money boys we are fine on our own! SHPG!

BEast Mode!! You cant buy out the IRISH!

Dip and rip baby! Great news no BUYOUT :) just shows how strong the IRISH are GO SHPG

TAKE YOUR 60 BILLION BACK HOME JAPANESE

Looking GREAT SHPG!!!

Shire shareholders approve $32 bln Baxalta merger (5/27/16)

By Ian Walker

LONDON--Shareholders of Dublin-based pharmaceutical company Shire PLC SHP Friday approved the company's proposed $32 billion merger with Bannockburn, Ill-based Baxalta Incorporated at the general meeting, and the deal is expected to close on June 3.

Shire Chief Executive Flemming Ornskov said: "The combination will allow us to realize our goal of building the leading global biotechnology company focused on rare diseases and other highly specialized conditions, offering greater opportunities for our patients, healthcare partners and employees."

Shire and Baxalta announced their deal in January. The two companies signed off on the deal after overcoming fears the tie-up could run afoul of U.S. laws that prohibit tax-free spinoffs from being used as a device to funnel cash to shareholders. Baxalta was separated from parent Baxter International Inc. in July.

Shire agreed to pay $18 in cash plus 0.1482 of its American depository shares for each Baxalta share, making it one of the few ever cash-and-stock deals involving a recent tax-free spinoff.

Early last month, the Treasury Department imposed new rules that make it harder for companies to move their tax addresses out of the U.S. and then shift profits to low-tax countries using a maneuver known as earnings stripping.

Completion of the merger remains subject to approval by Baxalta shareholders, with a vote scheduled for 12GMT Friday, and other customary closing conditions, Shire said.

http://www.marketwatch.com/story/shire-shareholders-approve-32-bln-baxalta-merger-2016-05-27

Baxalta Shareholders Vote to Approve Combination (5/27/16)

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.

Earlier today, Shire shareholders of approximately 93.8 percent of the votes cast voted in favor of the adoption of the merger agreement with Baxalta. This represents approximately 75.5 percent of Shire’s total outstanding shares of common stock as of 8:00 a.m. (London time) on May 25, 2016, the record date for the special meeting.

As announced on January 11, 2016, Baxalta and Shire entered into a definitive merger agreement pursuant to which Shire would acquire Baxalta in a stock and cash transaction. Baxalta stockholder approval and Shire shareholder approval are conditions to the merger. The completion of the transaction remains subject to certain other closing conditions, but the companies expect that this transaction will be completed on or about June 3, 2016.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.

http://www.businesswire.com/news/home/20160527005380/en/Baxalta-Shareholders-Vote-Approve-Combination

Baxalta Announces Date for Special Meeting of Stockholders to Vote on Combination With Shire (4/14/16)

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) announced today that the special meeting of stockholders to adopt the merger agreement with Shire plc (LSE:SHP, NASDAQ:SHPG) will be held on May 27, 2016, at 7:00 a.m. Central Time, for shareholders of record as of the close of business on April 11, 2016. The special meeting will be held at Baxalta’s corporate headquarters, located at 1200 Lakeside Drive, Bannockburn, Illinois 60015.

For more information, please refer to the merger proxy on Form S-4 that Shire has filed with the Securities and Exchange Commission (SEC).

About Baxalta

Baxalta Incorporated (NYSE:BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.

http://www.businesswire.com/news/home/20160414006544/en/Baxalta-Announces-Date-Special-Meeting-Stockholders-Vote

Not only is Valeant Pharmaceuticals (NYSE:VRX) reportedly prepping a bid for Salix Pharmaceuticals (NASDAQ:SLXP), but Shire (NASDAQ:SHPG) is now rumored to be preparing an offer.
Shire has taken initial steps towards a bid and is evaluating how to secure financing, sources told Reuters.
Yesterday, Valeant Pharmaceuticals (VRX) was reported to be arranging financing for a takeout of Salix at a likely price of more than $150 per share. Including net debt, Salix is valued at almost $11B.
Previously: Valeant close to a bid for Salix (Feb. 12 2015)
SLXP +1.2% premarket
http://seekingalpha.com/news/2297376-shire-now-on-the-hunt-for-salix#

ABBV BoD recommends dropping SHPG merger: #msg-107254974.

ABBV wavering on SHPG tax-inversion merger:

http://finance.yahoo.com/news/announcement-notice-shire-abbvie-board-234400720.html

Annotations on phase-2b studies of ABT-493/ABT-530: #msg-106413637.

Shire Plc. [$SHPGF] due diligence

bullish
note ticker symbol is SHPGF not -Y
takeover play

$SHPGF

DD Notes ~ http://www.ddnotesmaker.com/SHPGF

##### recent news/filings ~ source: finance.yahoo.com

Wed, 02 Jul 2014 18:18:24 GMT ~ AbbVie courts shareholders to put pressure on Shire over bid
[at Financial Times] - The chief executive of AbbVie has urged Shire shareholders to press the FTSE 100 pharmaceutical group to engage with the US company regarding its £27bn takeover approach. AbbVie's Richard Gonzalez flew ...
read full: http://www.ft.com/cms/s/6328e50a-0206-11e4-9af7-00144feab7de,s01=1.html
*********************************************************

Sun, 29 Jun 2014 20:42:12 GMT ~ AbbVie takes pursuit of Shire to shareholders
[at Financial Times] - AbbVie will this week step up its pursuit of Shire when the US drugmaker's chief executive flies into London to pitch a proposed £27bn takeover to shareholders. Richard Gonzalez will hold talks with Shire ...
read full: http://www.ft.com/cms/s/78cb9386-ffc1-11e3-9a4a-00144feab7de,s01=1.html
*********************************************************

Fri, 27 Jun 2014 21:36:47 GMT ~ Nomad at heart of Shire's defence
[at Financial Times] - Born in Denmark and commuting between his office in Boston and his home in Zurich, Flemming Ornskov is the ultimate global businessman. It is an appropriately nomadic lifestyle for the chief executive ...
read full: http://www.ft.com/cms/s/d5ae41ca-fddc-11e3-bd0e-00144feab7de,s01=1.html
*********************************************************

Wed, 25 Jun 2014 16:30:44 GMT ~ Shire / AbbVie: let's have a war
[at Financial Times] - The battle is not joined, but the war-dances are great fun. Shire, the target, performed its haka last week, shouting of organic growth. On Wednesday, it was the bidder's turn. AbbVie's ritual had several ...
read full: http://www.ft.com/cms/s/4dc97488-fc78-11e3-86dc-00144feab7de,s01=1.html
*********************************************************

Wed, 25 Jun 2014 13:24:03 GMT ~ AbbVie lays out case for Shire takeover
[at Financial Times] - AbbVie said it wanted to "move quickly and cooperatively" to strike a deal with Shire as it set out plans for a £27bn takeover of its UK-listed rival. The US drugmaker said a deal would create ...
read full: http://www.ft.com/cms/s/bb482c10-fc60-11e3-98b8-00144feab7de,s01=1.html
*********************************************************



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SHPGF/company-info
Ticker: $SHPGF
OTC Market Place: OTCQB
CIK code: 0000936402
Company name: Shire Plc.
Company website: http://www.shire.com
Incorporated In: United Kingdom

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000936402&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/SHPGF/filings
Latest financials: http://www.otcmarkets.com/stock/SHPGF/financials
Latest news: http://www.otcmarkets.com/stock/SHPGF/news - http://finance.yahoo.com/q/h?s=SHPGF+Headlines

Major holdings: http://data.cnbc.com/quotes/SHPGF/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=SHPGF+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/SHPGF.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=SHPGF

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=SHPGF&search=search

DTCC: http://search2.dtcc.com/?q=Shire+Plc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Shire+Plc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Shire+Plc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.shire.com
Alexa: http://www.alexa.com/siteinfo/http://www.shire.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.shire.com

Short Sales: http://www.otcmarkets.com/stock/SHPGF/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/SHPGF/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/SHPGF/research
Historical Prices: http://finance.yahoo.com/q/hp?s=SHPGF+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=SHPGF+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=SHPGF+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=SHPGF+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=SHPGF+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=SHPGF+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=SHPGF
Balance Sheet: http://finance.yahoo.com/q/bs?s=SHPGF
Cash Flow: http://finance.yahoo.com/q/cf?s=SHPGF+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/SHPGF
Bloomberg: http://www.bloomberg.com/quote/SHPGF:US
Morningstar: http://quotes.morningstar.com/stock/s?t=SHPGF
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SHPGF
Barchart: http://www.barchart.com/quotes/stocks/SHPGF
OTC Short Report: http://otcshortreport.com/index.php?index=SHPGF
Investopedia: http://www.investopedia.com/markets/stocks/SHPGF/?wa=0

http://www.pennystocktweets.com/stocks/profile/SHPGF

##### last known share structure ~ source: otcmarkets.com

Market Value: $44,411,927,454 a/o Jul 03, 2014
Shares Outstanding: 562,532,330 a/o Apr 27, 2012
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/SHPGF
fi2